J
Jean-Marc Ferrero
Researcher at Institut Jules Bordet
Publications - 85
Citations - 7219
Jean-Marc Ferrero is an academic researcher from Institut Jules Bordet. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 26, co-authored 53 publications receiving 5984 citations.
Papers
More filters
Journal ArticleDOI
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain,José Baselga,Sung-Bae Kim,Jungsil Ro,Vladimir Semiglazov,Mario Campone,Eva Ciruelos,Jean-Marc Ferrero,Andreas Schneeweiss,Sarah Heeson,Emma Clark,Graham Ross,Mark C. Benyunes,Javier Cortes,Abstr Act +14 more
TL;DR: In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzuab and docetaxel, as compared with the additionof placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination.
Journal ArticleDOI
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain,Sung-Bae Kim,Javier Cortes,Jungsil Ro,Vladimir Semiglazov,Mario Campone,Eva Ciruelos,Jean-Marc Ferrero,Andreas Schneeweiss,Adam Knott,Emma Clark,Graham Ross,Mark C. Benyunes,José Baselga +13 more
TL;DR: A significant improvement in overall survival is shown with pertuzumab, trastuzumAB, and docetaxel in patients with HER2-positive metastatic breast cancer, compared with placebo,trastuzuab, anddocetaxe and this regimen represents a substantial improvement on the standard of care.
Journal ArticleDOI
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
Thomas Bachelot,Céline Bourgier,Claire Cropet,Isabelle Ray-Coquard,Jean-Marc Ferrero,Gilles Freyer,Sophie Abadie-Lacourtoisie,Jean-Christophe Eymard,Marc Debled,Dominique Spaeth,Eric Legouffe,D. Allouache,Claude El Kouri,Eric Pujade-Lauraine +13 more
TL;DR: It is suggested that tamoxifen plus everolimus increased CBR, TTP, and overall survival compared with tamoxIFen alone in postmenopausal women with AI-resistant mBC.
Journal ArticleDOI
Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases From HER2-positive Metastatic Breast Cancer (LANDSCAPE): A Single-Group Phase 2 Study
Thomas Bachelot,Gilles Romieu,Mario Campone,Véronique Diéras,Claire Cropet,Florence Dalenc,Marta Jimenez,Emilie Le Rhun,Jean-Yves Pierga,Anthony Gonçalves,Marianne Leheurteur,Julien Domont,Maya Gutierrez,Hervé Curé,Jean-Marc Ferrero,Catherine Labbe-Devilliers +15 more
TL;DR: The combination of lapatinib and capecitabine is active as first-line treatment of brain metastases from HER2-positive breast cancer and a phase 3 trial is warranted.
Journal ArticleDOI
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop,Sung-Bae Kim,Antonio González-Martín,Patricia LoRusso,Jean-Marc Ferrero,Melanie Smitt,Ron Yu,Abraham C. F. Leung,Hans Wildiers +8 more
TL;DR: The final PFS analysis and the first interim overall survival analysis showed a trend favouring trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent DM1 linked to trastzumab, with treatment of physician's choice in this population of patients.